Cancer Immunotherapy
Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).
Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.
-
(2R,3S)-Emricasan
0 ImagesCat. No.: HY-10396ACAS No.: 409369-54-6Synonyms: (2R,3S)-PF 03491390; (2R,3S)-IDN-6556
-
GFH018 methylbenzenesulfonate
0 ImagesCat. No.: HY-160215ACAS No.: 2345717-52-2GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma.
-
MC-GGFG-AM-(10NH2-11F-Camptothecin)
0 ImagesCat. No.: HY-156514CAS No.: 2987938-97-4MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research.
-
Spiraeoside (Standard)
0 ImagesCat. No.: HY-N8253RCAS No.: 20229-56-5Synonyms: Quercetin 4′-O-glucoside (Standard)Spiraeoside (Standard) is the analytical standard of Spiraeoside. This product is intended for research and analytical applications. Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits reactive oxygen species (ROS) and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities.
-
CXCR4 antagonist 6
0 ImagesCat. No.: HY-146401CAS No.: 2304750-68-1CXCR4 antagonist 6 (compound 46) is a potent CXCR4 antagonist with an IC50 value of 79 nM. CXCR4 antagonist 6 inhibits CXCL12 induced cytosolic calcium flux (IC50 = 0.25 nM). CXCR4 antagonist 6 significantly mitigates CXCL12/CXCR4 mediated cell migration. CXCR4 antagonist 6 exhibits marked efficacy in a cancer metastasis model in mice.
-
hA2AAR antagonist 1
0 ImagesCat. No.: HY-163701CAS No.: 2842150-81-4hA2AAR antagonist 1 (compound 4a) is a highly selective hA2AAR antagonist with a Ki of 5 nM. hA2AAR antagonist 1 can be used in the study of immune-oncology.
-
AR antagonist 17
0 ImagesCat. No.: HY-178148CAS No.: 3064715-04-1AR antagonist 17 is a selective, orally active, low brain-penetrant Androgen Receptor (AR) antagonist (IC50 = 0.010 μM), effectively blocking AR dimerization and nuclear translocation, and demonstrating potent efficacy in several castration-resistant prostate cancer (CRPC) cells. AR antagonist 17 showed superior efficacy against variant drug-resistant AR mutants. AR antagonist 17 can inhibit tumor growth in an LNCaP xenograft model without apparent toxicity. AR antagonist 17 can be used for the study of castration-resistant prostate cancer (CRPC).
-
CCR2-RA
0 ImagesCat. No.: HY-50084CAS No.: 512177-31-0
-
Nerolidol-d4
0 ImagesCat. No.: HY-N1944SNerolidol-d4 is deuterated labeled Nerolidol (HY-N1944). Nerolidol has multiple natural membrane activities, possesses anti-cancer, anti-inflammatory, antibacterial and anti-insect activity. Nerolidol Suppresses parasitic activity, suppresses bloodsucking diseases, bloodworm diseases, and other diseases. Nerolidol can protect the cells from lipid and protein properties, damage to DNA, and protect the cells from damage.
-
Anticancer peptoid 1
0 ImagesCat. No.: HY-P11658CAS No.: 620948-14-3Synonyms: Peptoid 1Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer.
-
ALD-PEG4-OPFP
0 ImagesCat. No.: HY-136127CAS No.: 1324007-10-4ALD-PEG4-OPFP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
TrxR1-IN-1
0 ImagesCat. No.: HY-149390CAS No.: 3052303-04-2TrxR1-IN-1 (Compound 5j) is a TrxR1 inhibitor (IC50: 8.8 μM). TrxR1-IN-1 has anticancer activity, with IC50s of MCF-7 (1.5 μM), HeLa (1.7 μM), BGC-823 (2.4 μM), SW-480 (2.8 μM), A549 (2.1 μM). TrxR1-IN-1 has antioxidant activity, and scavenges DPPH radical.
-
Phomoxanthone A
0 ImagesCat. No.: HY-126640CAS No.: 359844-69-2Phomoxanthone A is a xanthone dimer, which can be isolated from Phomopsis. Phomoxanthone A exhibits antimalarial and antitubercular activities against Plasmodium falciparum (K1, multidrug-resistant strain, IC50 is 0.11 µg/mL) and Mycobacterium tuberculosis (H37Ra strain, MIC is 0.50 µg/mL). Phomoxanthone A exhibits cytotoxicity in cells KB, BC-1 and Vero, IC50 is 0.99, 0.51 and 1.4 µg/mL, respectively.
-
CT-1119
0 ImagesCat. No.: HY-P992338CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors.
-
TLR7/8 agonist 4 hydroxy-PEG10-acid
0 ImagesCat. No.: HY-139018CAS No.: 2388520-17-8TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
-
LYA914
0 ImagesCat. No.: HY-175455LYA914 is an orally effective AR/AR-V7 PROTAC degrader. LYA914 recruits CRBN to target and bind the conserved DBD domain of AR and AR-V7, inducing their ubiquitination and subsequent degradation, thereby completely blocking AR signaling and transcriptional activity. LYA914 can be used for the research of castration-resistant prostate cancer.
-
NCGC-023
0 ImagesCat. No.: HY-187678CAS No.: 3024011-79-5NCGC-023 is a LATS1/2 inhibitor. NCGC-023 selectively inhibits LATS1/2, an upstream regulator of Yap in the Hippo signaling pathway, increases the expression of active Yap protein, activates Yap-dependent signaling pathways, triggers non-Yap-dependent metallothionein-mediated heavy metal responses, and upregulates IL-33-related regenerative responses. NCGC-023 can be used in studies related to gastrointestinal acute radiation syndrome (GI-ARS).
-
Camalexin (Standard)
0 ImagesCamalexin (Standard) is the analytical standard of Camalexin. This product is intended for research and analytical applications. Camalexin is a phytoalexin isolated from Camelina sativa (Cruciferae) with antibacterial, antifungal, antiproliferative and anticancer activities. Camalexin can induce reactive oxygen species (ROS) production[1][2][3].
